A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome

Background: Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening thrombotic microangiopathy (TMA), which has been treated successfully with eculizumab. The optimal duration of eculizumab in treating patients with aHUS remains poorly defined. Methods: We conducted a multicenter retro...

Descripción completa

Detalles Bibliográficos

Autores principales:	Saeed AlZabali, Sawsan AlBatati, Khawla Rahim, Hassan Faqeehi, Abubaker Osman, Abdulaziz Bamhraz, Mohammed A. Saleh, Jameela A. Kari, Majed Aloufi, Loai Eid, Haydar Nasser, Abubakr Imam, Entesar AlHammadi, Omar Alkandari, Mohammed Al Riyami, Sidharth Sethi, Christoph Licht, Khalid A. Alhasan, Abdulkarim AlAnazi
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	MDPI AG 2022-11-01
Colección:	Children
Materias:	atypical hemolytic uremic syndrome discontinuation of eculizumab thrombotic microangiopathy HUS relapse
Acceso en línea:	https://www.mdpi.com/2227-9067/9/11/1734
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!